deoxycytidine has been researched along with Genetic Predisposition in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Arentsen-Peters, STCJM; Castro, PG; Cheung, LC; Chua, GA; Dolman, MEM; Jones, L; Kerstjens, M; Koopmans, B; Kotecha, RS; Molenaar, JJ; Pieters, R; Pinhanҫos, SS; Schneider, P; Singh, S; Stam, RW; Wander, P; Zwaan, CM | 1 |
| Che, X; Cheng, X; Du, Z; Huang, X; Li, J; Lin, D; Shao, M; Tan, W; Wang, C; Wu, C; Zhao, Y; Zheng, J | 1 |
| Bamlet, WR; Bentrem, DJ; Etheridge, AS; Glubb, D; Gordân, R; Innocenti, F; Jiang, C; Kindler, HL; Kubo, M; McLeod, H; McWilliams, RR; Mulkey, F; Nakamura, Y; Neel, N; Niedzwiecki, D; Owzar, K; Petersen, GM; Ratain, MJ; Seiser, E; Sibley, AB; Talamonti, MS; Van Loon, K; Venook, AP; Yeh, JJ | 1 |
| Jiménez Gordo, AM; López Gómez, M | 1 |
| Hong, D; Hong, W; Kou, JY; Mao, WM; Su, D; Wang, K; Wang, XJ; Xie, FJ; Yu, XM; Zhang, YP | 1 |
| Bara, I; Chang, GC; Chen, YM; Cheng, A; Fuerte, F; Ho, J; Jin, K; Kurnianda, J; Ladrera, G; Lee, JS; Lee, V; Liao, M; Liu, HE; Margono, B; Mok, T; Pan, H; Qian, X; Sandoval-Tan, J; Seetalarom, K; Srimuninnimit, V; Sriuranpong, V; Sun, Y; Syahruddin, E; Thongprasert, S; Truman, M; Wang, J; Wu, YL; Yu, CJ; Zhang, L; Zhou, C; Zhu, Y | 1 |
| DU, ZL; Huang, Y; Jin, J; Li, YX; Lin, DX; Qiao, Y; Ren, H; Tan, W; Yu, DK | 1 |
| Cheung, DY; Jeong, M; Kang, CS; Kim, HS; Kim, IK; Kim, JI; Kim, TJ; Seo, JH | 1 |
| Bai, LY; Chang, IC; Chang, JY; Chao, Y; Chen, JS; Chen, LT; Chiang, NJ; Chiu, CF; Ho, CL; Hsieh, RK; Hsu, C; Huang, SF; Lee, KD; Rau, KM; Shan, YS; Shiah, HS; Tsai, CS; Tsou, HH; Yang, Y; Yen, CJ; Yu, MS | 1 |
| Acharyya, S; Bilger, M; Haaland, B; Lopes, G; Tan, PS | 1 |
| Chan, SH; Koo, SX; Ngeow, J | 1 |
| Antonini, NF; Gelderblom, H; Guchelaar, HJ; Kweekel, DM; Nortier, JW; Punt, CJ; Van der Straaten, T | 1 |
| Jain, M; Mittal, B; Singh, H | 1 |
| Hasegawa, R; Kamatani, N; Kaniwa, N; Kawamoto, M; Kim, SR; Kim, WY; Lee, SJ; Lee, SS; Okuda, H; Saito, Y; Sawada, J; Shin, JG; Sugiyama, E; Tohkin, M | 1 |
| Kopper, L; Tímár, J | 1 |
| Alonso, MR; Benítez, J; Caronia, D; de la Torre, J; Díaz-Rubio, E; García-Sáenz, JA; González-Neira, A; Martin, M; Moreno, LT; Pita, G; Sastre, J | 1 |
3 review(s) available for deoxycytidine and Genetic Predisposition
| Article | Year |
|---|---|
Nowadays pancreatic cancer prognosis.
Topics: Aged; Aged, 80 and over; Albumin-Bound Paclitaxel; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Comorbidity; Deoxycytidine; Diabetes Mellitus; Diet; Drug Resistance, Neoplasm; Early Detection of Cancer; Fluorouracil; Gemcitabine; Genetic Predisposition to Disease; Humans; Irinotecan; Leucovorin; Neoadjuvant Therapy; Neoplasm Metastasis; Oxaliplatin; Palliative Care; Pancreatectomy; Pancreatic Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Prognosis; Radiosurgery; Risk Factors; Spain | 2019 |
Pancreatic adenocarcinosarcoma of monoclonal origin: a case report.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Biopsy; CA-19-9 Antigen; Cell Differentiation; Deoxycytidine; DNA Mutational Analysis; Exons; Gemcitabine; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Magnetic Resonance Imaging; Male; Neoplasms, Complex and Mixed; Pancreatic Neoplasms; Phenotype; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sarcoma; Tomography, X-Ray Computed; Up-Regulation | 2014 |
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: results by performance status, EGFR mutation, hi
Topics: Antineoplastic Agents; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease Progression; Disease-Free Survival; Docetaxel; Drug Substitution; ErbB Receptors; Gemcitabine; Genetic Predisposition to Disease; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Markov Chains; Monte Carlo Method; Mutation; Neoplasm Staging; Pemetrexed; Phenotype; Protein Kinase Inhibitors; Risk Factors; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2015 |
5 trial(s) available for deoxycytidine and Genetic Predisposition
| Article | Year |
|---|---|
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Immunological; Bevacizumab; Cell Line, Tumor; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Gemcitabine; Genetic Predisposition to Disease; Genome-Wide Association Study; Humans; Male; Middle Aged; Pancreatic Neoplasms; Polymorphism, Single Nucleotide; Receptors, Calcitriol; RNA, Messenger; Vitamin D | 2018 |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Topics: Administration, Intravenous; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; Deoxycytidine; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
[Impact of CCND1 A870G polymorphism on acute adverse events in postoperative rectal cancer patients treated with adjuvant concurrent chemoradiotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy, Adjuvant; Cyclin D1; Deoxycytidine; Diarrhea; Female; Fluorouracil; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Single Nucleotide; Postoperative Period; Prospective Studies; Rectal Neoplasms; Risk Factors | 2013 |
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Cetuximab; Deoxycytidine; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Organoplatinum Compounds; Phenotype; Proportional Hazards Models; Proto-Oncogene Proteins p21(ras); Taiwan; Time Factors; Treatment Outcome | 2015 |
Glutathione-S-transferase pi (GSTP1) codon 105 polymorphism is not associated with oxaliplatin efficacy or toxicity in advanced colorectal cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Codon; Colorectal Neoplasms; Deoxycytidine; Epidemiologic Methods; Female; Fluorouracil; Genetic Predisposition to Disease; Genotype; Glutathione S-Transferase pi; Humans; Male; Middle Aged; Neurotoxicity Syndromes; Organoplatinum Compounds; Oxaliplatin; Polymorphism, Genetic; Treatment Outcome | 2009 |
8 other study(ies) available for deoxycytidine and Genetic Predisposition
| Article | Year |
|---|---|
Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease Management; Disease Models, Animal; Drug Evaluation, Preclinical; Gemcitabine; Gene Rearrangement; Genetic Predisposition to Disease; Humans; Infant; Myeloid-Lymphoid Leukemia Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2020 |
Functional role of BTB and CNC Homology 1 gene in pancreatic cancer and its association with survival in patients treated with gemcitabine.
Topics: Antimetabolites, Antineoplastic; Basic-Leucine Zipper Transcription Factors; Blotting, Western; Cell Proliferation; Deoxycytidine; Female; Gemcitabine; Gene Expression Profiling; Genetic Predisposition to Disease; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Male; Middle Aged; Neovascularization, Pathologic; Pancreatic Neoplasms; Real-Time Polymerase Chain Reaction; Survival Analysis; Treatment Outcome | 2018 |
Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Carcinoma, Non-Small-Cell Lung; China; Deoxycytidine; Female; Gemcitabine; Genetic Markers; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Outcome Assessment, Health Care; Polymorphism, Single Nucleotide; Prevalence; Reproducibility of Results; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2013 |
Genetic predisposition resulting in sinusoidal obstruction syndrome in a patient with resected sigmoid cancer on adjuvant oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Fluorouracil; Genetic Predisposition to Disease; Glutathione Transferase; Hepatic Veno-Occlusive Disease; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Oxaloacetates; Sigmoid Neoplasms | 2016 |
Role of TGF-beta1 (-509C>T) promoter polymorphism in susceptibility to cervical cancer.
Topics: Adult; Deoxycytidine; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Heterozygote; Homozygote; Humans; India; Middle Aged; Neoplasm Staging; Odds Ratio; Polymorphism, Single Nucleotide; Promoter Regions, Genetic; Risk Factors; Smoking; Thymidine; Tobacco, Smokeless; Transforming Growth Factor beta1; Uterine Cervical Neoplasms | 2009 |
Ethnic differences of two non-synonymous single nucleotide polymorphisms in CDA gene.
Topics: Alleles; Antimetabolites, Antineoplastic; Antirheumatic Agents; Asian People; Black or African American; Black People; Cytarabine; Cytidine Deaminase; Deoxycytidine; Gemcitabine; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide; White People | 2009 |
[Validation study of KRAS mutation in colorectal cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Genes, ras; Genetic Predisposition to Disease; Genetic Testing; Humans; Leucovorin; Male; Mutation; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Pathology, Molecular; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Treatment Outcome | 2009 |
A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Base Sequence; Binding Sites; Breast Neoplasms; Capecitabine; Cell Line, Tumor; Colorectal Neoplasms; Cytidine Deaminase; Deoxycytidine; E2F Transcription Factors; Erythema; Female; Fluorouracil; Foot Dermatoses; Genetic Association Studies; Genetic Predisposition to Disease; Hand Dermatoses; Haplotypes; Humans; Logistic Models; Male; Middle Aged; Pain; Polymorphism, Single Nucleotide; Prodrugs; Promoter Regions, Genetic; Sequence Analysis, DNA; Syndrome; Transcription, Genetic | 2011 |